Ethic Inc’s Viking Therapeutics VKTX Stock Holding History

Ethic Inc’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,748	Closed	-$448K	–	1303
2025 Q1	$448K	Buy	18,748 +13,683	+270%	+$432K	0.01%	824
2024 Q4	$204K	Buy	+5,065	New	+$289K	﹤0.01%	1058

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ethic Inc's VKTX Position: Q2 2025 in Review

Ethic Inc sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 18,748 shares — an estimated $448K sold.

Ethic Inc first reported a position in VKTX in Q4 2024 and held it in 2 quarters. The position peaked at $448K in Q1 2025. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Ethic Inc reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Ethic Inc sold 18,748 Viking Therapeutics shares in Q2 2025, an estimated $448K.
Ethic Inc first reported a position in Viking Therapeutics in Q4 2024 and held it in 2 quarters.
Ethic Inc's Viking Therapeutics position peaked at $448K in Q1 2025.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Ethic Inc's 13F filing for Q2 2025, filed 30 Jul 2025.